Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases

Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24

Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Shilpa's CDMO customer placed binding purchase order

Gavi outlines plans to support access to new vaccines

The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030

Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030

Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia

Investing in Malaysia's largest clinic operator to expand the healthcare business